July 25, 2018 by Chain Drug Review
Ian Read, Kirsten Lund-Jurgensen, Pfizer
Leading Headlines, Supplier News
NEW YORK — Pfizer announced it will increase its commitment to U.S. manufacturing with a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients around
July 11, 2018 by Chain Drug Review
Albert Bourla, Angela Hwang, biosimilars, Ian Read, John Young, Michael Goettler, Pfizer, Pfizer Consumer Healthcare
Business, Leading Headlines, Supplier News
NEW YORK — Pfizer Inc. announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These
November 14, 2017 by Chain Drug Review
Albert Boura, Angela Hwang, Ian Read, John Young, Pfizer, Pfizer Innovative Health
Business, Pharmacy, Supplier News
NEW YORK — In a fine-tuning of its executive leadership, Pfizer Inc. has named Albert Bourla as chief operating officer, a newly created position. Pfizer said Bourla, 56, currently group president of the Pfizer Innovative Health business unit, is slated to start in the COO role on Jan. 1. With the move, chairman and chief
October 11, 2017 by Chain Drug Review
Albert Bourla, Ian Read, Pfizer, Pfizer Consumer Healthcare, Pfizer Innovative Health
Business, Featured Articles, Leading Headlines, Pharmacy, Supplier News
NEW YORK — Pfizer Inc. is assessing strategic options for its Pfizer Consumer Healthcare subsidiary, including a potential sale. The pharmaceutical giant said this week that it’s considering “a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction.” However, the company noted that it may decided
September 26, 2016 by Chain Drug Review
Frank D’Amelio, Ian Read, Pfizer, Pfizer Essential Health, Pfizer Innovative Health
Business, Leading Headlines, Pharmacy, Supplier News
NEW YORK — Pfizer says that it’s not going to split up. The pharmaceutical giant announced Monday that, following an extensive evaluation, its board of directors and executive leadership team decided to keep the company’s current structure and not pursue a separation of Pfizer Innovative Health and Pfizer Essential Health into their own publicly traded
August 22, 2016 by Chain Drug Review
Albert Bourla, David Hung, Ian Read, Medivation, oncology, Pfizer, Pfizer Innovative Health, XTANDI
Business, Pharmacy, Supplier News
NEW YORK — Boosting its oncology portfolio, Pfizer Inc. plans to acquire biopharmaceutical company Medivation for $14 billion in cash. Under the deal announced Monday, Pfizer is paying $81.50 a share in cash for San Francisco-based Medivation, whose products include XTANDI (enzalutamide), an androgen receptor inhibitor that the companies said is the nation’s leading novel
April 16, 2016 by Chain Drug Review
Allergan, Brent Saunders, Ian Read, inversion deals, Pfizer
2016, Issue 04-18-2016, Issues, News
NEW YORK — Pfizer Inc. and Allergan PLC have, by mutual agreement, terminated their planned merger. Pfizer management attributed the decision to new tax rules issued by the Treasury Department that are specifically intended to make such combinations less attractive. Under the proposed merger, Pfizer would have shifted its corporate address — but not its
February 8, 2016 by Chain Drug Review
Allergan, Brent Saunders, Ian Read, Pfizer
Business, Leading Headlines, Pharmacy, Supplier News
NEW YORK — Pfizer Inc. has announced the executive leadership team following the completion of its acquisition of Allergan plc. The pharmaceutical giant said Monday that, as announced previously, Allergan chief executive officer Brent Saunders will become president and chief operating officer of the merged company, overseeing Pfizer and Allergan’s combined commercial businesses, manufacturing and
December 7, 2015 by John Schultz and Chain Drug Review
Allergan, Ian Read, Pfizer, tax inversions
2015, Issue 12-07-2015, Issues, News, Pharmacy
NEW YORK — Despite widespread criticism over the issue of tax inversions, legal experts say that current regulatory restrictions in the United States are unlikely to block the $160 billion merger deal announced by U.S. pharmaceutical giant Pfizer and Ireland-based drug manufacturer Allergan Inc. Generally, tax inversions involve a U.S. firm reincorporating in a low-tax
November 23, 2015 by Chain Drug Review
Allergan, Brent Saunders, Ian Read, Pfizer
Leading Headlines, Pharmacy, Supplier News
NEW YORK and DUBLIN, Ireland — Pfizer Inc. plans to acquire Allergan Inc. for about $160 billion in the biggest deal ever in the health care sector. Pfizer said Monday that the transaction will allow the New York-based drug giant to relocate to Ireland to cut its U.S. tax burden. “The proposed combination of Pfizer
April 17, 2015 by John Schultz and Chain Drug Review
Ian Read, John Castellani, Kenneth Frazier, Pharmaceutical Research and Manufacturers of America, PhRMA
Leading Headlines, Supplier News
WASHINGTON — John Castellani, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), plans to retire next year. PhRMA said Thursday that Castellani’s retirement is slated to go into effect Jan. 1, 2016. “Representing the biopharmaceutical industry has been one of the most rewarding experiences of my career, and I am